All data are based on the daily closing price as of March 28, 2025
m
Medy-Tox
086900.KQ
89.42 USD
0.61
+0.69%
Overview
Last close
89.42 usd
Market cap
588.27M usd
52 week high
187.48 usd
52 week low
77.92 usd
Target price
138.33 usd
Valuation
P/E
N/A
Forward P/E
30.03
Price/Sales
3.7754
Price/Book Value
1.8525
Enterprise Value
602.42M usd
EV/Revenue
3.8731
EV/EBITDA
22.5974
Key financials
Revenue TTM
155.54M usd
Gross Profit TTM
94.28M usd
EBITDA TTM
27.42M usd
Earnings per Share
N/A usd
Dividend
2.99 usd
Total assets
474.21M usd
Net debt
N/A usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.